Actelion Pharmaceuticals Ltd

act-128800 - ponesimod

 

Study ID Status Type Title
AC-058A200 Completed Results Summary Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subjects with moderate to severe chronic plaque psoriasis
AC-058A201 Completed Results Summary Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety & tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, administered up to twenty-eight weeks in patients with moderate to severe chronic plaque psoriasis